Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast: subset analysis of patients with scalp psoriasis in the phase 3 POETYK PSO-1 and PSO-2 trials

被引：0
|
作者：
Foley, Peter [1 ]
机构：
[1] Skin Hlth Inst, Carlton, Vic, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2022年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [21] Deucravacitinib in moderate to severe plaque psoriasis: Correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
    Rubel, Diana
    Armstrong, April W.
    Papp, Kim
    Zhuo, Joe
    Becker, Brandon
    Zhong, Yichen
    Beaumont, Jennifer
    DeRosa, Michael
    Kisa, Renata M.
    Banerjee, Subhashis
    Strober, Bruce
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 71 - 72
  • [22] Deucravacitinib Improves Psoriasis Symptoms and Signs Diary Domain Scores in Patients With Moderate to Severe Plaque Psoriasis: Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies
    Armstrong, April W.
    Strober, Bruce
    Gordon, Kenneth
    Zhuo, Joe
    Becker, Brandon
    Kisa, Renata
    Throup, John
    Kim, Jonghyeon
    Dirschka, Thomas
    Papp, Kim Alexander
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 : 24 - 25
  • [23] Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe psoriasis: Findings from the phase 3 POETYK PSO-3 and PSO-4 trials
    Foley, Peter
    Zhang, Jianzhong
    Imafuku, Shinichi
    Ding, Yangfeng
    Okubo, Yukari
    Li, Hui
    Tada, Yayoi
    Li, Linfeng
    Ohtsuki, Mamitaro
    Pan, Weili
    Lu, Yan
    Hao, Cheng
    Xian, Jiang
    Ho, Ji-Chen
    Guo, Shuping
    Seo, Seong Jun
    Napoli, Andrew
    Chatterjee, Arkendu
    Kisa, Renata M.
    Banerjee, Subhashis
    Morita, Akimichi
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 28 - 29
  • [24] Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials
    Armstrong, April W.
    Lebwohl, Mark
    Warren, Richard B.
    Sofen, Howard
    Morita, Akimichi
    Paul, Carle
    Papp, Kim A.
    Colombo, Matthew J.
    Scotto, Julie
    Vaile, John
    Zhuo, Joe
    Vritzali, Eleni
    Berger, Victoria
    Schroeder, Georgene
    Banerjee, Subhashis
    Thaci, Diamant
    Strober, Bruce
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
  • [25] Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)
    Strober, Bruce
    Blauvelt, Andrew
    Warren, Richard B.
    Papp, Kim A.
    Armstrong, April W.
    Gordon, Kenneth B.
    Morita, Akimichi
    Alexis, Andrew F.
    Lebwohl, Mark
    Foley, Peter
    Kisa, Renata M.
    Colston, Elizabeth
    Wang, Tao
    Banerjee, Subhashis
    Thaci, Diamant
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (08) : 1543 - 1554
  • [26] Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
    Lebwohl, Mark
    Warren, Richard
    Imafuku, Shinichi
    Bagel, Jerry
    Armstrong, April W.
    Passeron, Thierry
    Banerjee, Subhashis
    Kisa, Renata M.
    Colombo, Matthew J.
    Scharnitz, Thomas
    Hoyt, Kim
    Thaci, Diamant
    Blauvelt, Andrew
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 565 - 567
  • [27] Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
    Blauvelt, Andrew
    Rich, Phoebe
    Sofen, Howard
    Strober, Bruce
    Merola, Joseph F.
    Lebwohl, Mark
    Morita, Akimichi
    Szepietowski, Jacek C.
    Lambert, Jo
    Hippeli, Lauren
    Colston, Elizabeth
    Balagula, Eugene
    Banerjee, Subhashis
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 775 - 782
  • [28] Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
    Warren, Richard
    Armstrong, April W.
    Imafuku, Shinichi
    Morita, Akimichi
    Paul, Carle
    Augustin, Matthias
    Passeron, Thierry
    Kircik, Leon
    Vritzali, Eleni
    Scharnitz, Thomas
    Schroeder, Georgene
    Banerjee, Subhashis
    Strober, Bruce
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2310 - 2312
  • [29] Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials (vol 14, pg 2235, 2024)
    Armstrong, April W.
    Augustin, Matthias
    Beaumont, Jennifer L.
    Pham, Tan P.
    Hudgens, Stacie
    Gordon, Kenneth B.
    Zhuo, Joe
    Becker, Brandon
    Zhong, Yichen
    Kisa, Renata M.
    Banerjee, Subhashis
    Papp, Kim A.
    DERMATOLOGY AND THERAPY, 2025, : 1037 - 1044
  • [30] Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials
    Lebwohl, Mark
    Warren, Richard B.
    Kircik, Leon
    Colston, Elizabeth
    Hippeli, Lauren
    Napoli, Andrew
    Kisa, Renata M.
    Banerjee, Subhashis
    Menter, Alan
    Thaci, Diamant
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB35 - AB35
12345